公开(公告)号：EP3194574B1

公开(公告)日：2023-06-07

申请号：EP15763506.1

申请日：2015-08-25

发明人： MARG, Andreas ,  SPULER, Simone

IPC分类号： C12N5/077 ,  A61P21/02 ,  A61P21/04 ,  A61K35/34

公开(公告)号：EP2327763B1

公开(公告)日：2018-03-14

申请号：EP10179257.0

申请日：2006-08-04

申请人： Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH ,  Max-Delbrück-Centrum für Molekulare Medizin (MDC)

发明人： Schendel, Dolores ,  Wilde, Susanne ,  Blankenstein, Thomas

IPC分类号： C12N5/10 ,  C07K14/725 ,  C12N15/12 ,  C12N5/0783 ,  C12N5/0784 ,  A61K39/00 ,  C07K14/705

CPC分类号： C07K14/705 ,  A61K2039/5154 ,  A61K2039/5156 ,  C12N5/0636 ,  C12N5/0639 ,  Y02A50/386 ,  Y02A50/412

摘要： The present invention is directed to a method of generating antigen specific T cells. Furthermore, the invention is directed to antigen specific T cells, isolated transgenic TCR's, pharmaceutical compositions containing same and their use in adoptive cell therapy. This invention in particular pertains to the use of cells co-expressing allogeneic MHC molecules and antigens to induce peptide-specific T cells from non-selected allogeneic T cell repertoires.

公开(公告)号：EP2018185B1

公开(公告)日：2016-08-31

申请号：EP07719268.0

申请日：2007-04-26

申请人： Universidade Federal de Minas Gerais ,  Max-Delbrück-Centrum für Molekulare Medizin (MDC)

发明人： SOUZA DOS SANTOS, Robson Augusto ,  SOUSA SANTOS, Sergio Henrique ,  ALVAREZ LEITE, Jaqueline Isaura ,  MATOS DE MOURA, Marina ,  SIQUEIRA HAIBARA, Andrea ,  RODRIQUES FERNANDEZ, Luciana ,  BADER, Michael ,  ALENINA, Natalia ,  SINISTERRA, Rubens Dario

IPC分类号： A61K45/00 ,  A61K38/08 ,  A61K31/415 ,  A61P3/00 ,  G01N33/50

CPC分类号： A61K31/415 ,  A61K38/085 ,  G01N33/68 ,  G01N33/6893 ,  G01N2333/726 ,  G01N2500/00

公开(公告)号：EP2041171B1

公开(公告)日：2015-05-20

申请号：EP07726131.1

申请日：2007-06-22

申请人： Max-Delbrück-Centrum für Molekulare Medizin (MDC)

发明人： BLANKENSTEIN, Thomas ,  UCKERT, Wolfgang ,  KIEBACK, Elisabeth ,  CHARO, Jehad

IPC分类号： C07K14/705 ,  C07K19/00 ,  C12N15/62 ,  C12N5/10 ,  A61K35/14 ,  A61K38/17 ,  A61K48/00

CPC分类号： C07K14/7051 ,  A61K38/00 ,  A61K38/177 ,  A61K48/00 ,  A61K2035/124 ,  A61K2039/5158 ,  C07K2319/20 ,  C07K2319/21 ,  C07K2319/23 ,  C07K2319/40 ,  C07K2319/41 ,  C07K2319/43 ,  C12N15/62 ,  C12N15/79

摘要： The present invention relates to a method for selecting a host cell population expressing a functional fusion protein comprising at least one epitope-providing amino acid sequence (epitope-tag) and the amino acid sequence of a protein that is expressed on the surface of said host cell. Preferably, the amino acid sequence comprises an alpha or beta chain of a T-cell receptor. The present invention further relates to uses of said functional T-cell receptor (TCR) alpha or beta chain fusion protein in medicine, in particular in adoptive transfer.

公开(公告)号：EP2460890A1

公开(公告)日：2012-06-06

申请号：EP10193362.0

申请日：2010-12-01

申请人： Max-Delbrück-Centrum für Molekulare Medizin (MDC)

发明人： Bader, Michael ,  Öczelik, Cemil ,  Mühlstedt, Silke

IPC分类号： C12Q1/68

CPC分类号： C12Q1/6883 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2800/32

摘要： The present invention relates to the gene Gpnmb and its use as a genetic marker in the incidence of cardiovascular conditions and cardiac diseases, such as complications derived from myocardial infarction. Gpnmb provides a valuable tool both for diagnostic as well as therapeutic approaches, in order to treat or prevent cardiovascular conditions and cardiac diseases, in particular complications derived from myocardial infarction.

摘要翻译： 本发明涉及基因Gpnmb及其在心血管疾病和心脏病发病中的遗传标记物的用途，例如由心肌梗死引起的并发症。 Gpnmb为诊断和治疗方法提供了宝贵的工具，以治疗或预防心血管疾病和心脏疾病，特别是由心肌梗死引起的并发症。

公开(公告)号：EP2428228A1

公开(公告)日：2012-03-14

申请号：EP10195929.4

申请日：2010-12-20

申请人： Max Delbrück Centrum für Molekulare Medizin (MDC) Berlin-Buch;

发明人： Walther, Wolfgang ,  Kobelt, Dennis ,  Schlag, Peter M.

IPC分类号： A61K48/00

CPC分类号： A61K31/547 ,  A61K38/191 ,  A61K48/005 ,  A61K48/0066 ,  A61K2039/53 ,  C12N15/85 ,  C12N2800/24

摘要： The present invention relates to a linear DNA expression construct having covalently closed ends, comprising an expression cassette comprising a coding sequence encoding for a gene therapy anti-cancer agent for use in the treatment of cancer, wherein said DNA expression construct is suitable for administration into cells or tissues by a physical transfection method. Preferably, said DNA expression construct consists of a dumbbell-shaped circular strand of DNA.

摘要翻译： 本发明涉及具有共价闭合末端的线性DNA表达构建体，其包含编码用于治疗癌症的基因治疗抗癌剂的编码序列的表达盒，其中所述DNA表达构建体适于施用于 细胞或组织通过物理转染方法。 优选地，所述DNA表达构建体由DNA的哑铃状环状链构成。

公开(公告)号：EP2197906A1

公开(公告)日：2010-06-23

申请号：EP08802876.6

申请日：2008-10-13

申请人： Max-Delbrück-Centrum für Molekulare Medizin (MDC) ,  Humboldt Universität zu Berlin

发明人： FALK, Kirsten ,  RÖTZSCHKE, Olaf ,  LUCIUS, Richard

IPC分类号： C07K14/445 ,  A61K39/002 ,  C12N15/62

CPC分类号： C07K14/445 ,  A61K39/0008 ,  A61K39/001 ,  A61K39/35 ,  A61K39/385 ,  C07K2319/40 ,  Y02A50/401 ,  Y02A50/412 ,  Y02A50/414

摘要： The present invention relates to a fusion polypeptide comprising a) at least one fragment of the Plasmodium falciparum S-antigen or a variant thereof, wherein the fragment comprises one or a plurality of Plasmodium falciparum S-antigen repeat unit(s) or variant(s) thereof and b) at least one antigen different from the S-antigen. The present invention also relates to a pharmaceutical composition comprising that fusion polypeptide as well as to the use thereof for the treatment or prevention of an autoimmune disease, an allergic reaction, a transplantation-related complication, e.g. graft rejection or 'graft vs. host disease', and another inflammatory disease and a method for treatment or prevention of said conditions.

公开(公告)号：EP2164865A2

公开(公告)日：2010-03-24

申请号：EP08759248.1

申请日：2008-06-13

申请人： Hochschule Mannheim ,  Max-Delbrück-Centrum für Molekulare Medizin (MDC)

发明人： KIOSCHIS-SCHNEIDER, Petra ,  HAFNER, Mathias ,  AMMERSCHLÄGER, Manuel ,  RITZ, Sandra ,  HOLLOSCHI, Andreas ,  WANKER, Erich, E.

IPC分类号： C07K14/47 ,  C12N15/12 ,  C12N5/10 ,  A61P25/00 ,  A61P35/00 ,  A61K31/00 ,  A61K31/352 ,  A61K31/58

CPC分类号： A61K31/00 ,  A61K31/352 ,  A61K31/58 ,  G01N33/6896 ,  G01N2500/10 ,  G01N2800/2835

摘要： The present invention relates to tetranortriterpenoid compounds and pharmaceutical compositions thereof, which are provided for use in the treatment, diagnosis and/or prevention of trinucleotide repeat disorders (like a polyglutamine diseases, e.g Huntingdon's disease), amyloid diseases, neurodegenerative disease, protein misfolding diseases or tumors. The tetranortriterpenoid compounds of the present invention are further provided for the reduction and/or inhibition of the aggregation of amyloidogenic proteins, preferably of polyglutamine proteins (such as huntingtin) as well as for increasing proteasome activity. The present invention furthermore relates to nucleic acids, comprising the nucleotide sequences of two huntingtin fragments, as well as to cells and kits, which are useful in methods for assessing the aggregation of huntingtin and in methods for identifying compounds, which modulate the aggregation of huntingtin.

公开(公告)号：EP2160461A2

公开(公告)日：2010-03-10

申请号：EP08773780.5

申请日：2008-06-30

申请人： Max-Delbrück-Centrum für Molekulare Medizin (MDC)

发明人： IZSVAK, Zsuzsanna ,  IVICS, Zoltan ,  MATES, Lajos ,  MANOJ, Namitha ,  JUDIS, Carmen-Anisia ,  KATZER, Andrea

IPC分类号： C12N9/22 ,  C12N15/90

CPC分类号： C12N9/1241 ,  A61K38/45 ,  A61K48/00 ,  A61K48/0066 ,  C12N9/22 ,  C12N15/90 ,  C12N2800/90 ,  C12Y207/07

摘要： The present invention refers to hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB). The invention further refers to corresponding nucleic acids producing these variants, to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using these hyperactive variants of a transposase of the transposon system Sleeping Beauty (SB) and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or RSDs). Furthermore, applications of these transposase variants, the transpsoson, or the gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.

公开(公告)号：EP1785728A1

公开(公告)日：2007-05-16

申请号：EP05024949.9

申请日：2005-11-15

申请人： Max-Delbrück-Centrum für Molekulare Medizin (MDC) ,  Universität zu Lübeck

发明人： Bader, Michael ,  Shmidt, Tatiana ,  Hampich, Franziska ,  Hartmann, Enno ,  Köhler, Matthias

IPC分类号： G01N33/68 ,  G01N33/574 ,  A01K67/027

CPC分类号： G01N33/574 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  C07K14/4702 ,  C12N15/8509 ,  G01N33/57415 ,  G01N33/689 ,  G01N33/6893

摘要： The present invention relates to methods and devices for selecting of compounds that modulate the function of importin α 7, a method for producing a pharmaceutical and contraceptive composition, comprising a modulator, a respective pharmaceutical and contraceptive composition, transgenic non-human animals, and a method for contraception or for the treatment of a proliferative disease, breast cancer, and diabetes or a method of modifying spermatogenesis, comprising administering an effective amount of a modulator of importin α 7.

摘要翻译： 本发明涉及用于化合物的选择的方法和装置并调制输入蛋白±7的功能，用于生产药物和避孕组合物，其包括调制器，respectivement药物和避孕组合物，转基因非人类动物的方法，以及一 用于避孕或用于治疗增殖性疾病的，乳腺癌，和糖尿病或修改精子发生的方法，包括有效量的输入蛋白±第七的调节剂的施用方法